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Abstract
OBJECTIVE—To characterize the presence of Clostridium sordellii and Clostridium perfringens 
in the vagina and rectum, identify correlates of presence, and describe strain diversity and presence 
of key toxins.
METHODS—We conducted an observational cohort study in which we screened a diverse cohort 
of reproductive-aged women in the United States up to three times using vaginal and rectal swabs 
analyzed by molecular and culture methods. We used multivariate regression models to explore 
predictors of presence. Strains were characterized by pulsed-field gel electrophoresis and tested 
for known virulence factors by polymerase chain reaction assays.
RESULTS—Of 4,152 participants enrolled between 2010 and 2013, 3.4% (95% confidence 
interval [CI] 2.9–4.0) were positive for C sordellii and 10.4% (95% CI 9.5–11.3) were positive for 
C perfringens at baseline. Among the 66% with follow-up data, 94.7% (95% CI 88.0–98.3) of 
those positive for C sordellii and 74.4% (95% CI 69.0–79.3) of those positive for C perfringens at 
baseline were negative at follow-up. At baseline, recent gynecologic surgery was associated with 
C sordellii presence, whereas a high body mass index was associated with C perfringens presence 
in adjusted models. Two of 238 C sordellii isolates contained the lethal toxin gene, and none 
contained the hemorrhagic toxin gene. Substantial strain diversity was observed in both species 
with few clusters and no dominant clones identified.
CONCLUSION—The relatively rare and transient nature of C sordellii and C perfringens 
presence in the vagina and rectum makes it inadvisable to use any screening or prophylactic 
approach to try to prevent clostridial infection.
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Clostridia are Gram-positive, spore-forming, anaerobic bacteria commonly found in soil and 
are relatively uncommon human pathogens.1,2 Obstetric–gynecologic cases of Clostridium 
sordellii and Clostridium perfringens infections have resulted in a toxic shock-like 
syndrome2–17 (Reis T, Chaves C, Soares A, Moreira M, Boaventura L, Ribeiro G. A 
Clostridium sordellii fatal toxic shock syndrome post-medical-abortion in Portugal, 
presented at the 21st European Congress of Clinical Microbiology and Infectious Diseases, 
May 7–10, 2011, Milan, Italy) with a high fatality rate.
Cases of fatal pelvic clostridial infections have followed events including miscarriage, full-
term delivery, stillbirth, abortion, and cervical procedures. Eight of the deaths followed 
medical abortions with mifepristone and misoprostol, although no causal pathway has been 
identified.18 A disproportionate number of cases occurred in the western United States.
The emergence of clostridial infections affected medical abortion services in the United 
States. In 2006, the Planned Parenthood Federation of America changed its Medical 
Standards and Guidelines to recommend buccal over vaginal administration of misoprostol 
and to require routine use of antibiotics after medical abortion,19 most commonly 7 days of 
doxycycline or a single dose of azithromycin.20 Many independent abortion providers chose 
to adopt the same measures.
Because clostridial pelvic infections are very rare, this observational cohort study explores 
clostridial presence. Primary objectives include: estimating the prevalence of C sordellii and 
C perfringens in the vagina, rectum, or both; exploring how presence changes over time; and 
identifying predictors of presence in exploratory analyses. Secondary objectives included 
describing strain diversity and identifying the presence of key toxins in the isolated strains.
21,22
MATERIALS AND METHODS
Women aged 18–45 years not seeking or undergoing emergency or oncologic care were 
eligible to participate in the study. Twenty-five Metropolitan Statistical Areas were randomly 
selected weighted by population data from the 2007 U.S. Census. Counties were randomly 
selected within each Metropolitan Statistical Area (also weighted by population) within 
which suitable study sites were sought. Sites were selected to access a diverse patient 
population and included private obstetrics–gynecology practices, family planning clinics, 
abortion clinics, university hospital gynecology clinics, and research centers.
The study enrolled participants from November 2010 to April 2013, and participation 
involved up to three visits. Participants were screened for vaginal and rectal presence of C 
sordellii and C perfringens at the initial visit, were asked to return 2 weeks later for a second 
screening (which coincided with the follow-up visit for patients undergoing abortion), and 
participants who were positive at the second visit were asked to return for a third screening 
approximately 4 weeks after the second visit. After providing written informed consent, 
participants provided a detailed medical history, a study clinician took swab samples from 
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the vagina and from the rectum, measured vaginal pH, and prepared a Gram stain slide. All 
samples were obtained before any other procedures were performed. Additional diagnostics 
and care provided as part of the clinical visit were documented. Participants also completed 
a computer assisted self-interview survey to collect additional information on demographics, 
sexual and reproductive history, and other relevant behaviors. The survey was administered 
in either English or Spanish using online electronic data capture with DatStat Illume 4.11. 
At follow-up visits, vaginal and rectal swabs, vaginal pH, and Gram stains were collected. 
Participants underwent a physical examination and responded to a shortened version of the 
computer survey on behaviors and practices that occurred since the previous visit.
A central laboratory scored the Gram stains for bacterial vaginosis using Nugent Criteria23 
and screened swab specimens by culture and by polymerase chain reaction (PCR) for both C 
perfringens and C sordellii. During the pilot phase of the project when we tested the 
laboratory methods, PCR was better at detecting C perfringens and culture was better at 
detecting C sordellii; thus, a participant was considered “positive” if she had a positive result 
with either PCR or culture. Please refer to Appendix 2, available online at http://
links.lww.com/AOG/A751, for specifics of culture and PCR methods. All isolates obtained 
through the study were sent to the Centers for Disease Control and Prevention (CDC) for 
confirmatory identification using the MALDI Biotyper and strain typing by pulsed-field gel 
electrophoresis and PCR. Conventional multiplex PCR assays were used to test for toxins. 
Please refer to Appendix 3, available online at http://links.lww.com/AOG/A751, for specific 
primers and probes used.
We selected a sample size of 4,000 to estimate the prevalence for both species of 
Clostridium at either anatomical site with a precision of ± 1% points at baseline. This 
sample size would also yield a substantial number of isolates for study by the CDC. 
Prevalence estimates were generated in SPSS 19.0, and bivariate analyses and multivariate 
regression models were conducted using Stata 12.1.
Because bacteria are transferred easily between the rectum and vagina and thus presence at 
either site could result in a pelvic infection, we combined vaginal and rectal presence for 
analyses of predictors as well as for changes in presence over time. Because the pathways of 
exposure and risk may differ for these two bacteria, we analyzed predictors for each 
bacterial species separately. We used generalized estimating equations with robust standard 
error estimation and exchangeable correlation structures to account for clustering of the 
observations by study site to explore predictors for the presence of C sordellii and C 
perfringens at baseline and at time two. We explored any variable that was statistically 
significant in the bivariate analyses for inclusion in the final adjusted models. We tested for 
correlations between covariates and selected which variables to include in our final adjusted 
model based on model fit and biological plausibility. We used a threshold of statistical 
significance of 0.001 based on a critical α value of 0.15 for these exploratory analyses with 
a Bonferroni adjustment for the 150 variables tested.
The study was approved by the New England institutional review board, the Colorado 
Multiple institutional review board, the University of Arizona institutional review board, and 
the University of Cincinnati institutional review board.
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RESULTS
We found 26 suitable sites in 18 of the 25 randomly selected Metropolitan Statistical Areas. 
We enrolled and obtained baseline samples from 4,152 women; 2,755 women (66%) 
completed visit 2 procedures, and 255 of the 350 women positive at visit 2 (73%) completed 
visit 3 procedures (Fig. 1). The median days between visit 1 and visit 2 were 14 days (inter-
quartile range 13–17). Participants were approximately evenly distributed among the four 
census regions, had an average age of 28.6 years, and 36% were patients who were 
undergoing abortion. In addition to seeking abortion services, other common reasons for 
presenting included study participation (26%), well-woman visits (21%), and gynecologic 
complaints (6%).
At baseline, 12.7% (95% confidence interval [CI] 11.7–13.7) of participants were positive 
for either species at either anatomical site; 10.4% (95% CI 9.5–11.3) were positive for C 
perfringens and 3.4% (95% CI 2.9–4.0) for C sordellii. Rectal presence was more common 
than vaginal presence for both species with 9.8% (95% CI 8.9–10.7) and 1.2% (95% CI 0.9–
1.6) of samples screening positive for C perfringens, respectively, and 3.2% (95% CI 2.7–
3.8) and 0.2% (95% CI 0.1–0.4) for C sordellii. Few participants had both species present 
(1%, 95% CI 0.7–1.3); and few had the same species in both anatomic sites (0.6%, 95% CI 
0.4–0.9 for C perfringens and 0.05%, 95% CI 0.006–0.2 for C sordellii).
We tested more than 150 variables for associations with presence; Table 1 displays a small 
subset of these variables. In bivariate analysis, no statistically significant differences in 
presence of either species were found by age, race–ethnicity, household income, number of 
days since last menses, or vaginal pH. Predictors were rarely significant for both species.
In adjusted baseline models, having gynecologic surgery in the previous 3 months was 
significantly associated with C sordellii presence (Table 2; adjusted odds ratio [OR] 4.86, 
P5.001). For C perfringens, taking medication for a gastrointestinal disorder in the previous 
3 months (adjusted OR 2.00, P<.001), ever having a surgical intervention related to abortion 
(surgical abortion or a surgical completion of a medical abortion; adjusted OR 1.40, P=.
001), and body mass index (BMI, calculated as weight (kg)/[height (m)]2) of 35 or greater 
(adjusted OR 1.83, P<.001) were significantly associated with presence. Medical abortion 
was not associated with presence of either species.
Of the participants who tested positive at baseline, 94.7% (95% CI 88.0–98.3) of patients 
positive for C sordellii and 74.4% (95% CI 69.0–79.3) of those positive for C perfringens 
were no longer positive by visit 2 (Fig. 1). Women positive for clostridia at visit 1 were more 
likely than negative women to be positive at visit 2. No related serious adverse events were 
reported.
Changes in C sordellii and C perfringens presence between visits 1 and 2 were not 
significantly different when comparing patients who had undergone abortion and 
nonabortion patients, medical abortion and surgical abortion patients, and those taking 
antibiotics compared with those who did not take any antibiotics.
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In adjusted models for presence at visit 2, no variables were significant for C sordellii, 
although presence at baseline shows some relationship in the abortion participant-only 
model (Table 3). For C perfringens, lower education and presence at baseline show a strong 
association in the overall model, and BMI of 35 or greater and having two or more sexual 
partners since the previous visit shows some relationship. These results did not change when 
the analysis was restricted to women with 7–21 days between visits.
C perfringens isolates (n=212) and C sordellii isolates (n=238) were confirmed and 
characterized at the CDC. No C sordellii isolates were positive for hemorrhagic toxin and 
two (0.8%, 95% CI 0.1–3.0) were positive for lethal toxin. The two lethal toxin-positive 
isolates were from baseline rectal samples of surgical abortion participants from the West. 
Both participants tested negative for C sordellii at their second visit. Among the C 
perfringens isolates, 211 (99.5%, 95% CI 97.4–100) were positive for α toxin, and 175 
(82.5%, 95% CI 76.8–87.4) were positive for θ toxin; none was positive for β or ε toxin.
Substantial strain diversity was observed in both C sordellii and C perfringens with few 
clusters and no dominant clones identified for either species. Twelve indistinguishable C 
sordellii and 18 indistinguishable C perfringens were recovered from more than one 
participant, nearly all of which were from different geographic locations. Significant strain 
diversity was found even among isolates recovered from the same participant. There were 
seven instances in which C perfringens was recovered from both rectal and vaginal samples 
at the same visit; in six cases, the strains were different. Of 15 instances when a participant 
had C perfringens isolated from the same anatomical site across visits (eg, positive vaginal 
sample at visits 1 and 2), 13 had different strains. For C sordellii, one of two participants 
with positive rectal and vaginal samples at the same visit carried a different strain, and eight 
of nine cases with isolates from the same site at different visits had different strains.
DISCUSSION
This study documents that vaginal and rectal presence of C sordellii is relatively rare and 
presence of C perfringens is more common in our sample of reproductive-aged U.S. women. 
In our regression models for C sordellii, only gynecologic surgery in the previous 3 months 
appeared significant at baseline (likely reflecting the opportunity for organisms to be 
introduced), and nothing was significant at visit 2. For C perfringens, BMI of 35 or greater 
was found to be significantly associated with presence of the bacteria at baseline and 
approached significance at visit 2. We also witnessed a trend of increasing ORs with 
increasing BMI, which may reflect reduced bacterial diversity24,25 (and thus a more 
hospitable environment for clostridia) and a reduced ability for hygiene. Clostridial presence 
did not appear to be related to pregnancy status, antibiotic use, geographic region, or medical 
abortion.
From the women who screened positive and returned for a follow-up visit, we can infer that 
presence of C sordellii or C perfringens very rarely leads to adverse outcomes. Furthermore, 
it appears that the presence of these bacteria is transient with the majority of women 
screening positive changing status by the next study visit. As such, we prefer the term 
bacterial “presence” rather than “colonization” or “carriage.”
Chong et al. Page 5
Obstet Gynecol. Author manuscript; available in PMC 2018 February 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Because strains are usually only recovered and studied in cases of disease or death, the 
prevalence of strains containing virulence factors in a healthy population was not previously 
documented. For C sordellii, lethal toxin has been implicated in all the fatal cases in the 
literature, but only 2 of 238 strains in our sample contained that gene. Hemorrhagic toxin is 
also considered to play a large role in pathogenesis; however, no strains tested positive for 
this gene.
Although our sampling scheme was designed to enroll a diverse cohort of reproductive-aged 
women, the generalizability of this study’s findings should be approached with caution. We 
used the computer assisted self-interview survey to encourage more honest reporting of 
sensitive behaviors,26–28 but it is likely that there was still some underreporting, and this 
methodology may have been an obstacle for those participants who were less computer-
literate.
Use of swab samples is vulnerable to sampling error, where clostridia may be present but the 
swab did not capture the bacteria. Swab samples were chosen over stool samples for logistic 
reasons, but it likely resulted in an underestimate of the presence of clostridia in the rectum. 
In addition, it is possible that the two species were present on the swabs but were not 
detected by culture and PCR methods either because of the difficulty of isolating the 
clostridia from the high number of other bacteria present or because clostridia were present 
in such low quantities that they were undetectable. The number of false-positives was 
minimal for PCR as a result of the specificity of the primers used. The CDC confirmed 
identification of all viable culture isolates using matrix-assisted laser desorption ionization 
time-of-flight mass spectrometry, and 95.1% of the original identifications were correct.
Because C sordellii and C perfringens presence was relatively rare, we may not have had 
sufficient power to detect predictors of presence, especially at the second visit when one 
third of our sample was lost to follow-up. Cohen’s effect sizes comparing demographic 
characteristics of women who returned to those lost to follow-up at visit 2 were small (≤0.1), 
with the exception of region of residence which was medium (Cramer’s V=0.2) (women in 
the South were more likely to be lost to follow-up). Because our study was not designed to 
bring back participants who were negative at visit 2 for a third visit, we cannot make 
accurate estimations of reappearance rates (those who went from positive to negative and 
back to positive).
This study suggests that the chances are exceedingly small that a woman would have C 
sordellii present in the vagina, that the lethal toxin gene would be present in that particular 
strain, and that the bacteria would remain long enough in the vagina and conditions would 
be suitable for the bacteria to flourish and produce toxins.
The rarity and transient nature of C sordellii and C perfringens presence make it inadvisable 
to use any screening or prophylactic approach to try to prevent clostridial infection. Presence 
is not predicted by any particular characteristic that could be used to target certain 
subgroups. Furthermore, based on these data, use of antibiotics at the time of medical 
abortion would likely not be effective at reducing the presence of clostridia or reducing 
clostridial infection.
Chong et al. Page 6
Obstet Gynecol. Author manuscript; available in PMC 2018 February 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
Supported by an unrestricted research grant from an anonymous donor, who had no involvement in the study 
design, data collection or analysis, or writing of the results.
The findings and conclusions in this report are those of the authors and do not necessarily represent the official 
position of the Centers for Disease Control and Prevention.
References
1. Hatheway CL. Toxigenic clostridia. Clin Microbiol Rev. 1990; 3:66–98. [PubMed: 2404569] 
2. Ho CS, Bhatnagar J, Cohen AL, Hacker JK, Zane SB, Reagan S, et al. Undiagnosed cases of fatal 
Clostridium-associated toxic shock in Californian women of childbearing age. Am J Obstet 
Gynecol. 2009; 201:459.e1–7. [PubMed: 19628200] 
3. Fischer M, Bhatnagar J, Guarner J, Reagan S, Hacker JK, Van Meter SH, et al. Fatal toxic shock 
syndrome associated with Clostridium sordellii after medical abortion. N Engl J Med. 2005; 
353:2352–60. [PubMed: 16319384] 
4. Cohen AL, Bhatnagar J, Reagan S, Zane SB, D’Angeli MA, Fischer M, et al. Toxic shock associated 
with Clostridium sordellii and Clostridium perfringens after medical and spontaneous abortion. 
Obstet Gynecol. 2007; 110:1027–33. [PubMed: 17978116] 
5. Zane S, Guarner J. Gynecologic clostridial toxic shock in women of reproductive age. Curr Infect 
Dis Rep. 2011; 13:561–70. [PubMed: 21882086] 
6. Sinave C, Le Templier G, Blouin D, Léveillé F, Deland E. Toxic shock syndrome due to Clostridium 
sordellii: a dramatic postpartum and postabortion disease. Clin Infect Dis. 2002; 35:1441–3. 
[PubMed: 12439811] 
7. Zane SB, Berg CJ. Deaths from Clostridium sordellii after medical abortion (letter to the editor). N 
Engl J Med. 2006; 354:1646–7.
8. Aldape MJ, Bryant AE, Stevens DL. Clostridium sordellii infection: epidemiology, clinical findings, 
and current perspectives on diagnosis and treatment. Clin Infect Dis. 2006; 43:1436–46. [PubMed: 
17083018] 
9. Rorbye C, Petersen IS, Nilas L. Postpartum Clostridium sordellii infection associated with fatal 
toxic shock syndrome. Acta Obstet Gynecol Scand. 2000; 79:1134–5. [PubMed: 11130102] 
10. Bitti A, Mastrantonio P, Spigaglia P, Urru G, Spano AI, Moretti G, et al. A fatal postpartum 
Clostridium sordellii associated toxic shock syndrome. J Clin Pathol. 1997; 50:259–60. [PubMed: 
9155682] 
11. Sosolik RC, Savage BA, Vaccarello L. Clostridium sordellii toxic shock syndrome: a case report 
and review of the literature. Infect Dis Obstet Gynecol. 1996; 4:31–5. [PubMed: 18476062] 
12. McGregor JA, Soper DE, Lovell G, Todd JK. Maternal deaths associated with Clostridium sordellii 
infection. Am J Obstet Gynecol. 1989; 161:987–95. [PubMed: 2801850] 
13. Hogan SF, Ireland K. Fatal acute spontaneous endometritis resulting from Clostridium sordellii. 
Am J Clin Pathol. 1989; 91:104–6. [PubMed: 2910010] 
14. Soper DE. Clostridial myonecrosis arising from an episiotomy. Obstet Gynecol. 1986; 68(suppl):
26S–28S. [PubMed: 3737071] 
15. Golde S, Ledger WJ. Necrotizing fasciitis in postpartum patients. A report of four cases Obstet 
Gynecol. 1977; 50:670–3. [PubMed: 337196] 
16. Hao Y, Senn T, Opp JS, Young VB, Thiele T, Srinivas G, et al. Lethal toxin is a critical determinant 
of rapid mortality in rodent models of Clostridium sordellii endometritis. Anaerobe. 2010; 16:155–
60. [PubMed: 19527792] 
17. Meites E, Zane S, Gould C, C. sordellii Investigators. Fatal Clostridium sordellii infections after 
medical abortions. N Engl J Med. 2010; 363:1382–3. [PubMed: 20879895] 
Chong et al. Page 7
Obstet Gynecol. Author manuscript; available in PMC 2018 February 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
18. Winikoff B. Clostridium sordellii infection in medical abortion. Clin Infect Dis. 2006; 43:1447–8. 
[PubMed: 17083019] 
19. Fjerstad M, Trussell J, Lichtenberg ES, Sivin I, Cullins V. Severity of infection following the 
introduction of new infection control measures for medical abortion. Contraception. 2011; 83:330–
5. [PubMed: 21397090] 
20. Jones H, O’Connell White K, Lichtenberg ES, Paul M. Medical abortion provision in the United 
States. Contraception. 2014; 90:301.
21. Thiele TL, Stuber TP, Hauer PJ. Detection of Clostridium sordellii strains expressing hemorrhagic 
toxin (TcsH) and implications for diagnostics and regulation of veterinary vaccines. Vaccine. 2013; 
31:5082–7. [PubMed: 24016805] 
22. Stevens DL, Aldape MJ, Bryant AE. Life-threatening clostridial infections. Anaerobe. 2012; 
18:254–9. [PubMed: 22120198] 
23. Nugent R, Krohn MJ, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a 
standardized method of gram stain interpretation. J Clin Microbiol. 1991; 29:297–301. [PubMed: 
1706728] 
24. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Human gut microbes associated with obesity. Nature. 
2006; 444:1022–3. [PubMed: 17183309] 
25. Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE, et al. A core gut 
microbiome in obese and lean twins. Nature. 2009; 457:480–4. [PubMed: 19043404] 
26. Kissinger P, Rice J, Farley T, Trim S, Jewitt K, Margavio V, et al. Application of computer-assisted 
interviews to sexual behavior research. Am J Epidemiol. 1999; 149:950–4. [PubMed: 10342804] 
27. Ghanem KG, Hutton HE, Zenilman JM, Zimba R, Erbelding EJ. Audio computer assisted self-
interview and face to face interview modes in assessing response bias among STD clinic patients. 
Sex Transm Infect. 2005; 81:421–5. [PubMed: 16199744] 
28. Rogers SM, Willis G, Al-Tayyib A, Villarroel MA, Turner CF, Ganapathi L, et al. Audio computer 
assisted interviewing to measure HIV risk behaviours in a clinic population. Sex Transm Infect. 
2005; 81:501–7. [PubMed: 16326855] 
Chong et al. Page 8
Obstet Gynecol. Author manuscript; available in PMC 2018 February 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 1. 
Presence of Clostridium sordellii (CS) and Clostridium perfringens (CP) across study visits. 
Denominators in boxes not marked LTF (lost to follow-up) indicate the number of 
participants for whom usable specimens for that visit were available.
Chong. Presence of Clostridia Bacteria in Women. Obstet Gynecol 2016.
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o 
es
tim
at
e 
ro
bu
st
 s
ta
nd
ar
d 
er
ro
rs
 a
fte
r a
cc
ou
nt
in
g 
fo
r c
lu
ste
rin
g 
at
 th
e 
re
cr
ui
tm
en
t c
lin
ic
 o
r s
ite
 u
sin
g 
an
 ex
ch
an
ge
ab
le
 c
or
re
la
tio
n 
str
uc
tu
re
. A
dju
ste
d 
m
o
de
ls 
ar
e 
fu
lly
 a
dju
ste
d f
or 
all
 of
 th
e v
ar
ia
bl
es
 li
ste
d 
w
ith
 a
dju
ste
d e
sti
ma
tes
 in
 th
e r
esp
ect
ive
 c
o
lu
m
n.
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† C
om
bi
ne
d 
BM
I l
es
s t
ha
n 
18
.5
 w
ith
 B
M
I 1
8.
5–
24
.9
 as
 a 
re
su
lt 
of
 sm
al
l c
el
l s
iz
es
.
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